New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
08:07 EDTNVOZosano Pharma enters into license agreement with Novo Nordisk
Zosano Pharma announced that it has entered into an agreement with Novo Nordisk to develop a new transdermal presentation of semaglutide, an investigational proprietary human GLP-1 analogue, to be administered once weekly using Zosano's microneedle patch system for the treatment of type 2 diabetes. Initially, Zosano and Novo Nordisk will engage in collaborative efforts to carry out preclinical experiments to verify delivery of semaglutide using Zosano's microneedle patch system. Under the terms of the agreement, Zosano will grant Novo Nordisk a worldwide, exclusive license to develop and commercialize Novo Nordisk's proprietary GLP-1 analogues using Zosano's microneedle patch system. Potential payments to Zosano under the agreement include an upfront payment and additional payments upon achieving certain preclinical, clinical, regulatory and sales milestones. Such payments could total more than $60M for the first product and $55M for each additional product.
News For NVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
06:38 EDTNVONovo Nordisk rejects claims made by Baxter, Reuters says
Novo Nordisk (NVO) rejects claims made by Baxter (BAX) that the company used substances made by Baxter in its Novoeight haemophilia treatment, following Monday's ITC investigation announcement, reports Reuters, citing an email from Novo Nordisk. Reference Link
May 20, 2015
10:26 EDTNVOJanssen acquires licence from Novo Nordisk for autoimmune disease development
Novo Nordisk (NVO) announced it has signed an agreement with Janssen Biotech (JNJ) under which Janssen will acquire an exclusive global license to further develop and commercialize a clinical program focused on therapy within autoimmune diseases. The program targets modulation of certain immune cells via a cell surface receptor, specifically the NKG2D receptor. Terms of the agreement have not been disclosed.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use